Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.
He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.
Latest From Andrew McConaghie
Veklury is now the first US FDA-approved treatment for COVID-19, but its limited benefits means its lifespan as a blockbuster could be short.
Many clinicians doubt that aducanumab can really help slow the decline in Alzheimer’s patients – but US FDA could offer it the benefit of the doubt.
Timing means full EU approval could coincide with US FDA authorization later this year.
Vertex has become a biotech investor favorite amid the tumult of 2020, but the potential of its pipeline is now under question.
Analysts are confident that Pfizer/BioNTech’s mRNA vaccine will prove its safety and efficacy – but waiting a little longer for more robust data could be for the best.
The UK’s biotech sector sees investor interest surge during the pandemic, though IPO levels are still disappointing compared with recent years.